Investor Relations

Overview

Zogenix, Inc. (Nasdaq: ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
NASDAQ | ZGNX (Common Stock)
$10.25 - 0.38
Stock chart for: ZGNX.O.  Currently trading at $10.25 with a 52 week high of $21.65 and a 52 week low of $7.90.
Data as of 04/29/16 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.

Latest Presentations

Zogenix April 2016 Investor Presentation
Download Documentation

Recent News More

New Data on Zogenix's ZX008 for Dravet Syndrome to be Presented at 14th International Child Neurology Congress

Read More

Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2015 Financial Results

Read More

Investor Events More

Wednesday, November 18, 2015 11:00 a.m. ET
Zogenix, Inc. at Stifel 2015 Healthcare Conference